Abstract
Between April 1986 and March 1989, ten patients under 21 years of age with histologically confirmed malignant astrocytoma, received marrow-ablative chemotherapy with either thiotepa and Etoposide (five patients) or thiotepa, Etoposide and BCNU (five patients), followed by bone marrow ‘rescue’. Nine patients had glioblastoma multiforme (GBM), and one patient had an intrinsic brain stem anaplastic astrocytoma (AA). Seven patients were treated for recurrent tumor. Two patients who developed GBM as second malignancies were treated directly following surgical resection. One patient had received irradiation only for recently diagnosed cervical spinal cord GBM.
Thiotepa was administered at a total dose of 600–900 mg/M2 over three days, Etoposide was administered at a total dose of 1500 mg/M2 over three days, and BCNU was administered at a total dose of 600 mg/M2 over four days. Non-hematopoietic toxicities have been mainly transient, predictable and acceptable, consisting of oropharyngeal mucositis, cutaneous hyperpigmentation, erythema and desquamation.
Four patients achieved complete responses (CR), as determined by radiographic evaluation (CT and/or MRI) on day 28 post-marrow infusion. The mean remission duration of those with CR is 290 + days; two patients presently remain in remission. Two patients achieved partial responses (PR, greater than 50% tumor shrinkage) by day 28 post-marrow infusion; both developed disease progression, at day 61 and 94 post-marrow infusion, respectively. One patient, with a brain stem AA, had stable disease maintained for 13 months post-marrow infusion.
With a total (CR + PR) response rate of 60%, these regimens merit evaluation in broader categories of recurrent brain tumor patients, as well as in patients with newly-diagnosed GBM.
Similar content being viewed by others
References
Mortimer JE, Hewlett JS, Bay J, Livingston RB: High-dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas. J Neuro-oncol l: 269–273, 1983
Fingert HJ, Hochberg FH: Mega-dose chemotherapy with bone marrow rescue. Prog Exp Tumor Res 28: 67–78, 1984
Johnson DB, Thompson JM, Corwin JA, Smith MT, de Los Reyes RA, Daly MB, Lamaster D, Leff RS, Mercier R, Messerschmidt GL: Adjuvant high-dose BCNU and autologous bone marrow transplantation for high-grade malignant gliomas. In: Autologous Bone Marrow Transplantation. Proc 4th Int Symposium, The Univ. of Texas M.D. Anderson Cancer Center, Houston, 1989, eds. Dicke KA, Spitzer G, Jagannath S and Eringer-Hodges MJ, pp 457–461
August CS, Serota FT, Koch PA, Burkey E, Schlesinger H, Elkins WL, Evans AE, D'Angio GT. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation and allogeneic or autologous marrow reconstitution. J Clin Oncol 2: 609–616, 1984
Walker MD, Green SB, Byer DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G; Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wison CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Eng J Med 303: 1323–1329, 1980
Sposto R, Ertel IJ, Jenkin RDT, Boesel CP, Venes JP, Ortega JA, Evans AE, Wara W, Hammond D: The effectiveness of chemotherapy for treatment of high-grade astrocytoma in children: Results of a randomized trial. J Neurooncol 7: 165–177, 1989
Finlay JL, Goins SC: Brain tumors in children. III. Advances in chemotherapy. Am J Ped Hematol Oncol 9: 264–271, 1987
Carella AM, Giordano D, Santini G, Frassoni F, Podesta M, Van Lint MT, Bacigalupo A, Nati S, Vimercati R, Occhini D, Bistolfi F, Lucarelli G, Lercari G, Marmont AM: High-dose BCNU followed by autologous bone marrow infusion in glioblastoma multiforme. Tumori 67: 473–475, 1980
Sertoli MR, Marangolo M, Ardizzoni A, Santini G, Carella MA, Congiu M, Martinengo M, Rosti KG, Ravaioli A, Pronzato P, Conte PF, Rosso R, Marmont A: High-dose chemotherapy (HDC) plus autologous bone marrow transplantation (ABMR) in glioblastoma and small cell lung cancer. Bone Marrow Transplantation 1 suppl 1, 323, 1986
Brun del Re GP, Seiler R, Baumgartner C, Bucher U, Gossi U, Reulen HJ, Stern AC, Studer H, Veraguth P, Wagner HP: High-dose BCNU and autologous bone marrow transplantation for malignant astrocytoma grade III-IV. Bone Marrow Transplantation 1, suppl 1, 329, 1986
Johnson DB, Thompson JM, Corwin JA, Mosley KR, Smith MT, de Los Reyes RA, Daly MB, Petty AM, Lamaster D, Pierson WP, Ruxer RL, Leff RS, Messerschmidt GL: Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. J Clin Oncol 5: 783–789, 1987
Wolff SN, Fer MF, McKay CM, Hande KR, Hainsworth JD, Greco FA: High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: A phase I study. J Clin Oncol 1: 701–705, 1983
Wolff SN, Phillips GL, Fay JW, Herzig RH, Lazarus HM, Herzig GP: In: Autologous Bone Marrow Transplantation. Proc 1st Int Symposium, The Univ. of Texas M.D. Anderson Cancer Center, Houston, eds. Dicke KA, Spitzer G, Zander AR, 1985, pp 255–259
Leff RS, Thompson, JM, Daly MB, Johnson DB, Harden EA, Mercier RJ, Messerschmidt GL: Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 62: 32–35, 1988
Long J, Leff T, Daly M, Thompson J, Mercier R, Johnson D, Harden E, Messerschmidt G, Harman G: Phase II trial of high-dose etoposide and autologous bone marrow transplantation (ABMR) for treatment of progressive glioma. Proc Am Soc Clin Oncol 8: 92, 1989
Hochberg FH, Parker LM, Takvorian T, Canellos GP, Zervas NT: High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg 54: 455–460, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Finlay, J.L., August, C., Packer, R. et al. High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. J Neuro-Oncol 9, 239–248 (1990). https://doi.org/10.1007/BF02341155
Issue Date:
DOI: https://doi.org/10.1007/BF02341155